Retrieve available abstracts of 62 articles: HTML format
Single Articles
May 2025
ROLLE LD Coding Errors in Study of Lung Cancer Screening Guidelines and Adherence.
JAMA Oncol. 2025 May 29. doi: 10.1001/jamaoncol.2025.1624. PubMed
MARINELLO A, Ghigna MR, Rotow JK, Adeyelu T, et al Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell
Lung Cancer.
JAMA Oncol. 2025 May 29. doi: 10.1001/jamaoncol.2025.1293. PubMedAbstract available
RICCIUTI B, Fusco F, Cooper A, Garbo E, et al Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable
and Unresectable Stage III Non-Small Cell Lung Cancer.
JAMA Oncol. 2025 May 22. doi: 10.1001/jamaoncol.2025.1115. PubMedAbstract available
HEYWARD J, Lesko CR, Murray JC, Mehta HB, et al Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung
Cancer.
JAMA Oncol. 2025 May 8. doi: 10.1001/jamaoncol.2025.0985. PubMedAbstract available
April 2025
PIKE LRG, Yu H, Rusthoven CG Management of EGFR-Variant and ALK-Positive Non-Small Cell Lung Cancer Brain
Metastasis.
JAMA Oncol. 2025 Apr 3. doi: 10.1001/jamaoncol.2025.0188. PubMed
March 2025
ROLLE LD, Olazagasti C, Lopes G, Rodriguez E, et al USPSTF Lung Cancer Screening Guidelines and Disparities in Screening Adherence.
JAMA Oncol. 2025 Mar 20. doi: 10.1001/jamaoncol.2025.0230. PubMed
February 2025
SAAL J, Eckstein M, Ritter M, Brossart P, et al Dissection of Progressive Disease Patterns for a Modified Classification for
Immunotherapy.
JAMA Oncol. 2025;11:154-161. PubMedAbstract available
GODDARD KAB, Feuer EJ, Mandelblatt JS, Meza R, et al Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment
Efforts, 1975-2020.
JAMA Oncol. 2025;11:162-167. PubMedAbstract available
December 2024
RAKAEE M, Tafavvoghi M, Ricciuti B, Alessi JV, et al Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small
Cell Lung Cancer.
JAMA Oncol. 2024 Dec 26. doi: 10.1001/jamaoncol.2024.5356. PubMedAbstract available
November 2024
MALHOTRA J, Mambetsariev I, Gilmore G, Fricke J, et al Targeting CNS Metastases in Non-Small Cell Lung Cancer With Evolving Approaches
Using Molecular Markers: A Review.
JAMA Oncol. 2024 Nov 27. doi: 10.1001/jamaoncol.2024.5218. PubMedAbstract available
CHENG Y, Zhang W, Wu L, Zhou C, et al Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small
Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.
JAMA Oncol. 2024 Nov 14. doi: 10.1001/jamaoncol.2024.5019. PubMedAbstract available
CALI DAYLAN AE, Morgensztern D, Waqar SN Toripalimab For Extensive-Stage Small Cell Lung Cancer.
JAMA Oncol. 2024 Nov 14. doi: 10.1001/jamaoncol.2024.4958. PubMed
October 2024
ASAHINA H, Tsukita Y, Tozuka T Chemoimmunotherapy in Older Adults With Non-Small Cell Lung Cancer-Reply.
JAMA Oncol. 2024 Oct 24. doi: 10.1001/jamaoncol.2024.4757. PubMed
TU H, Zhang Y, You Z Chemoimmunotherapy in Older Adults With Non-Small Cell Lung Cancer.
JAMA Oncol. 2024 Oct 24. doi: 10.1001/jamaoncol.2024.4754. PubMed
September 2024
ZHANG L, Li J, Guo L Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung
Cancer.
JAMA Oncol. 2024 Sep 26. doi: 10.1001/jamaoncol.2024.4211. PubMed
SORIN M, Prosty C, Spicer JD Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung
Cancer-Reply.
JAMA Oncol. 2024 Sep 26. doi: 10.1001/jamaoncol.2024.4214. PubMed
HU C Stereotactic Body Radiotherapy for Medically Inoperable Early-Stage Non-Small
Cell Lung Cancer.
JAMA Oncol. 2024 Sep 19. doi: 10.1001/jamaoncol.2024.2905. PubMed
SWAMINATH A, Parpia S, Wierzbicki M, Kundapur V, et al Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small
Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.
JAMA Oncol. 2024 Sep 19:e243089. doi: 10.1001/jamaoncol.2024.3089. PubMedAbstract available
August 2024
HONG MH, Choi YJ, Ahn HK, Lim SM, et al Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior
EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial.
JAMA Oncol. 2024 Aug 15. doi: 10.1001/jamaoncol.2024.2640. PubMedAbstract available
CHENG H The Role of Lazertinib in Patients With EGFR-Variant Non-Small Cell Lung Cancer.
JAMA Oncol. 2024 Aug 15. doi: 10.1001/jamaoncol.2024.2607. PubMed
HATTON JN, Kucera J, Seastedt KP, de Andrade KC, et al Characterizing Lung Cancer in Li-Fraumeni Syndrome.
JAMA Oncol. 2024 Aug 1:e242511. doi: 10.1001/jamaoncol.2024.2511. PubMed
LEE JM Sublobar Resection vs Lobectomy for High-Risk Stage I Non-Small Cell Lung
Carcinoma.
JAMA Oncol. 2024 Aug 1. doi: 10.1001/jamaoncol.2024.2294. PubMed
ALTORKI N, Wang X, Damman B, Jones DR, et al Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A
Seconday Analysis of a Randomized Clinical Trial.
JAMA Oncol. 2024 Aug 1:e242491. doi: 10.1001/jamaoncol.2024.2491. PubMedAbstract available
July 2024
ROSS HJ, Kozono D, Wang XF, Urbanic JJ, et al Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small
Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
JAMA Oncol. 2024 Jul 25. doi: 10.1001/jamaoncol.2024.1897. PubMedAbstract available
TSAI CH, Chiang PH More Benefits of Tai Chi Than Aerobic Exercise in Patients With Advanced Lung
Cancer.
JAMA Oncol. 2024 Jul 3. doi: 10.1001/jamaoncol.2024.2453. PubMed
TAKEMURA N, Lin CC More Benefits of Tai Chi Than Aerobic Exercise in Patients With Advanced Lung
Cancer-Reply.
JAMA Oncol. 2024 Jul 3. doi: 10.1001/jamaoncol.2024.2456. PubMed
June 2024
CHUN SG, Hu C, Komaki RU, Timmerman RD, et al Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally
Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Oncol. 2024 Jun 27. doi: 10.1001/jamaoncol.2024.1841. PubMedAbstract available
DONG S, Wang Z, Zhang JT, Yan B, et al Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced
Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.
JAMA Oncol. 2024 Jun 13. doi: 10.1001/jamaoncol.2024.1779. PubMedAbstract available
May 2024
CHAUNZWA TL, Qian JM, Li Q, Ricciuti B, et al Body Composition in Advanced Non-Small Cell Lung Cancer Treated With
Immunotherapy.
JAMA Oncol. 2024 May 23. doi: 10.1001/jamaoncol.2024.1120. PubMedAbstract available
SORIN M, Prosty C, Ghaleb L, Nie K, et al Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.
JAMA Oncol. 2024;10:621-633. PubMedAbstract available
ROLFO C, Russo A The Chemoimmunotherapy Revolution in Resectable NSCLC-The Times They Are
A-Changin'.
JAMA Oncol. 2024;10:569-570. PubMed
April 2024
NORONHA V, Patil V, Menon N, Shah M, et al Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in
EGFR-Variant Lung Cancer-Long-Term Results of a Randomized Clinical Trial.
JAMA Oncol. 2024 Apr 25. doi: 10.1001/jamaoncol.2024.0584. PubMed
RODRIGUES G, Higgins KA, Rimner A, Amini A, et al American Radium Society Appropriate Use Criteria for Unresectable Locally
Advanced Non-Small Cell Lung Cancer.
JAMA Oncol. 2024 Apr 11. doi: 10.1001/jamaoncol.2024.0294. PubMedAbstract available
AKAMATSU H Locally Advanced Relapse May Not Be Equal to Stage 3 Non-Small Cell Lung Cancer.
JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0231. PubMed
TACHIHARA M, Tsujino K Locally Advanced Relapse May Not Be Equal to Stage 3 Non-Small Cell Lung
Cancer-Reply.
JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0234. PubMed
SZLOSAREK PW, Creelan BC, Sarkodie T, Nolan L, et al Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid
Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
JAMA Oncol. 2024;10:475-483. PubMedAbstract available
March 2024
ITO K, Suzuki Y, Sakaguchi T, Fujiwara K, et al Physical Activity Using a Wearable Device as an Alternative to Performance Status
in Patients With Advanced Lung Cancer.
JAMA Oncol. 2024 Mar 28. doi: 10.1001/jamaoncol.2024.0023. PubMedAbstract available
TSUKITA Y, Tozuka T, Kushiro K, Hosokawa S, et al Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell
Lung Cancer.
JAMA Oncol. 2024 Mar 7. doi: 10.1001/jamaoncol.2023.6277. PubMedAbstract available
PALMA DA, Bahig H, Hope A, Harrow S, et al Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and
Interstitial Lung Disease: A Nonrandomized Clinical Trial.
JAMA Oncol. 2024 Mar 7. doi: 10.1001/jamaoncol.2023.7269. PubMedAbstract available
KEREKES DM, Frey AE, Prsic EH, Tran TT, et al Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in
the US.
JAMA Oncol. 2024;10:342-351. PubMedAbstract available
January 2024
ARRIETA O, Cardenas-Fernandez D, Rodriguez-Mayoral O, Gutierrez-Torres S, et al Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and
Anorexia: A Randomized Clinical Trial.
JAMA Oncol. 2024 Jan 11. doi: 10.1001/jamaoncol.2023.5232. PubMedAbstract available
LESTER-COLL NH, Park HS Stereotactic Body Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer-Is
This the Future?
JAMA Oncol. 2024 Jan 11. doi: 10.1001/jamaoncol.2023.5856. PubMed
WU TC, Luterstein E, Neilsen BK, Goldman JW, et al Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative
Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer:
A Nonrandomized Controlled Trial.
JAMA Oncol. 2024 Jan 11. doi: 10.1001/jamaoncol.2023.6033. PubMedAbstract available
NOGUEIRA LM, Liu Y Wildfire Exposure and Lung Cancer Survival-Reply.
JAMA Oncol. 2024 Jan 4. doi: 10.1001/jamaoncol.2023.6126. PubMed
OZAKI A, Murakami M, Leppold C Wildfire Exposure and Lung Cancer Survival.
JAMA Oncol. 2024 Jan 4. doi: 10.1001/jamaoncol.2023.6123. PubMed
OKUMA Y, Kubota K, Shimokawa M, Hashimoto K, et al First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon
EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
JAMA Oncol. 2024;10:43-51. PubMedAbstract available
December 2023
WEST HJ, Kim JY Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.
JAMA Oncol. 2023 Dec 28. doi: 10.1001/jamaoncol.2023.5276. PubMedAbstract available
SHIRAISHI Y, Kishimoto J, Sugawara S, Mizutani H, et al Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for
Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical
Trial.
JAMA Oncol. 2023 Dec 21. doi: 10.1001/jamaoncol.2023.5258. PubMedAbstract available
TEWARI KS, Colombo N, Monk BJ, Dubot C, et al Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for
Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses from the
KEYNOTE-826 Randomized Clinical Trial.
JAMA Oncol. 2023 Dec 14. doi: 10.1001/jamaoncol.2023.5410. PubMedAbstract available
TAKEMURA N, Cheung DST, Fong DYT, Lee AWM, et al Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in
Patients With Advanced Lung Cancer: A Randomized Clinical Trial.
JAMA Oncol. 2023 Dec 7. doi: 10.1001/jamaoncol.2023.5248. PubMedAbstract available
November 2023
BONNER SN, Curley R, Love K, Akande T, et al Structural Racism and Lung Cancer Risk: A Scoping Review.
JAMA Oncol. 2023 Nov 30. doi: 10.1001/jamaoncol.2023.4897. PubMedAbstract available
WANG VE, Gainor JF Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR
Mutations-Chasing Unicorns?
JAMA Oncol. 2023 Nov 22. doi: 10.1001/jamaoncol.2023.5004. PubMed
KIM TW, Bedard PL, LoRusso P, Gordon MS, et al Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With
Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
JAMA Oncol. 2023;9:1574-1582. PubMedAbstract available
GENSHEIMER MF, Gee H, Shirato H, Taguchi H, et al Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR
Phase 2 Nonrandomized Controlled Trial.
JAMA Oncol. 2023;9:1525-1534. PubMedAbstract available
October 2023
CHOI E, Ding VY, Luo SJ, Ten Haaf K, et al Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the
US.
JAMA Oncol. 2023 Oct 26. doi: 10.1001/jamaoncol.2023.4447. PubMedAbstract available
SEQUIST LV, Warner ET, Yang CJ Improving Eligibility Criteria for Lung Cancer Screening-Promises, Challenges,
and Unmet Needs.
JAMA Oncol. 2023 Oct 26. doi: 10.1001/jamaoncol.2023.4410. PubMed
JEMAL A, Schafer EJ, Sung H, Bandi P, et al The Burden of Lung Cancer in Women Compared With Men in the US.
JAMA Oncol. 2023 Oct 12. doi: 10.1001/jamaoncol.2023.4415. PubMed
TAKAHASHI N, Hao Z, Villaruz LC, Zhang J, et al Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small
Cell Lung Cancer: A Randomized Clinical Trial.
JAMA Oncol. 2023 Oct 12. doi: 10.1001/jamaoncol.2023.4025. PubMedAbstract available
September 2023
ALDEA M, Marinello A, Guyon D, Gazzah A, et al Prevalence of Thromboembolic Events in Patients With Non-Small Cell Lung Cancer
and RET Fusions.
JAMA Oncol. 2023 Sep 14. doi: 10.1001/jamaoncol.2023.3625. PubMed
TACHIHARA M, Tsujino K, Ishihara T, Hayashi H, et al Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced
Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
JAMA Oncol. 2023 Sep 7. doi: 10.1001/jamaoncol.2023.3309. PubMedAbstract available
GRECO L Patients With Brain Metastases Deserve Better-A Hard-Won Perspective.
JAMA Oncol. 2023;9:1197-1198. PubMed
SPAAS M, Sundahl N, Kruse V, Rottey S, et al Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in
Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical
Trial.
JAMA Oncol. 2023;9:1205-1213. PubMedAbstract available